Overview
Neumora Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to brain diseases, with a pipeline targeting depression, schizophrenia, and other psychiatric disorders through novel receptor-targeted mechanisms. Their lead asset navacaprant is a kappa opioid receptor antagonist in Phase 3 trials for major depressive disorder.
More in Neuropharmaceuticals
Latest industry news
Precision Neuroscience Raises $250M to Accelerate Brain-Computer Interface Development
2026-11-01 · Funding
Merge Labs Gets Competition as New Rival Neurotech Startup Enters the Consumer BCI Arena
2026-10-31 · Industry
Neuralink Connects to Grok AI Agent, Enabling ALS Patient to Control AI and Make Calls by Thought Alone
2026-10-30 · Product
Implanted BCIs Still Lack a Shared Safety Rulebook, and the Field Is Running Out of Time to Write One
2026-10-29 · Research
Company details
Category
💊 Neuropharmaceuticals
Location
South San Francisco, USA
Funding
Public · NASDAQ: NRXS
Website
www.neumoratherapeutics.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →